LENZ Therapeutics Inc (LENZ): Next-Year EPS Estimate 27.26%
As of 2026-05-12, LENZ Therapeutics Inc (LENZ) has a next-year EPS growth estimate of 27.26%.
On 2026-05-12, analyst consensus for LENZ's next-year EPS growth shifted from 25.03% to 27.26% — a positive change of 2.23 percentage points. Current-year growth is projected at -56.22%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 27.26%
- EPS growth this year
- -56.22%
- EPS next quarter (est)
- -$1.05
- Last price
- $7.53
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-12 | 27.26% | -56.22% | -$1.05 | $7.53 |
| 2026-05-11 | 25.03% | -37.80% | -$1.05 | $9.99 |
| 2026-05-10 | 25.03% | -37.80% | -$1.05 | $10.06 |
| 2026-05-07 | 25.03% | -37.80% | -$1.05 | $9.72 |
| 2026-05-06 | 25.03% | -37.80% | -$1.05 | $9.68 |
| 2026-05-05 | 25.03% | -37.80% | -$1.05 | $9.07 |
| 2026-05-04 | 25.03% | -37.80% | -$1.05 | $9.28 |
| 2026-05-03 | 25.03% | -37.80% | -$1.05 | $8.88 |
| 2026-04-30 | 25.03% | -37.80% | -$1.05 | $8.98 |
| 2026-04-29 | 25.03% | -37.80% | -$1.05 | $9.05 |
| 2026-04-28 | 25.03% | -37.80% | -$1.05 | $9.29 |
| 2026-04-27 | 25.03% | -37.80% | -$1.05 | $9.76 |
| 2026-04-26 | 25.03% | -37.80% | -$1.05 | $9.38 |
| 2026-04-24 | 25.03% | -37.80% | -$1.05 | $9.38 |
| 2026-04-23 | 25.03% | -37.80% | -$1.05 | $9.15 |
| 2026-04-20 | 30.54% | -30.98% | -$1.01 | $10.13 |
| 2026-04-19 | 30.54% | -30.98% | -$1.01 | $10.18 |
| 2026-04-16 | 30.54% | -30.98% | -$1.01 | $9.64 |
| 2026-04-15 | 30.54% | -30.98% | -$1.01 | $9.58 |
| 2026-04-14 | 30.54% | -30.98% | -$1.01 | $9.90 |
| 2026-04-13 | 30.54% | -30.98% | -$1.01 | $9.63 |
| 2026-04-12 | 31.51% | -30.43% | -$1.01 | $9.07 |
| 2026-04-10 | 31.51% | -30.43% | -$1.01 | $9.06 |
| 2026-04-09 | 31.51% | -30.43% | -$1.01 | $9.29 |
| 2026-04-08 | 31.51% | N/A | -$1.01 | $9.45 |
| 2026-04-07 | 31.51% | N/A | -$1.01 | $9.71 |
| 2026-04-06 | 31.51% | N/A | -$1.01 | $9.71 |
| 2026-04-05 | 31.51% | N/A | -$1.01 | $9.67 |
| 2026-04-03 | 31.51% | N/A | -$1.01 | $9.71 |
| 2026-04-02 | 31.51% | N/A | -$1.01 | $9.71 |
Recent News
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ for the Treatment of Presbyopia in the United KingdomGlobeNewswire
- LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...GuruFocus.com
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
- What To Expect From LENZ Therapeutics Inc (LENZ) Q4 2025 EarningsGuruFocus.com
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is LENZ Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-05-12, LENZ Therapeutics Inc (LENZ) has a next-year EPS growth estimate of 27.26%, based on analyst consensus.
When was the latest EPS estimate revision for LENZ?▾
The most recent revision occurred on 2026-05-12, when analysts adjusted the next-year EPS growth estimate from 25.03% to 27.26%.
What sector and industry does LENZ Therapeutics Inc belong to?▾
LENZ Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. LENZ appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. LENZ Therapeutics Inc (LENZ) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports